Innoviva (INVA) EBIT Growth (1y) (2011 - 2026)
Innoviva (INVA) EBIT Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -24.89% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 2,150.96% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 80.62% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 8.65% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 145.20% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Innoviva | 1.57 Bn | 969.11 Mn | 75.83 Mn | -7.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.90% |
| Dec 31, 2025 | -31.16% |
| Sep 30, 2025 | 0.83% |
| Jun 30, 2025 | -10.85% |
| Mar 31, 2025 | 346.51% |
| Dec 31, 2024 | -60.22% |
| Sep 30, 2024 | -5.76% |
| Jun 30, 2024 | 274.70% |
| Mar 31, 2024 | 22.46% |
| Dec 31, 2023 | 36.31% |
| Sep 30, 2023 | 83.13% |
| Jun 30, 2023 | -30.20% |
| Mar 31, 2023 | -46.22% |
| Dec 31, 2022 | -70.77% |
| Sep 30, 2022 | -73.50% |
| Jun 30, 2022 | -124.90% |
| Mar 31, 2022 | -24.69% |
| Dec 31, 2021 | 6.28% |
| Sep 30, 2021 | 220.47% |
| Jun 30, 2021 | 27.38% |